Akcea Therapeutics () and Ionis Pharmaceuticals (IONS), announced that Waylivra has received conditional marketing authorization from the European Commission, or EC, as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.
https://thefly.com/landingPageNews.php?id=2904769
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.